Cynthia Arbeeny
Company: Mitotherapeutix
Job title: Chief Scientific Officer
Seminars:
10.15 am MITO-1041: A Unique Liver-Directed siRNA Approach to Treat Mitochondrial Dysregulation in MASH 10:15 am
Mitochondrial dysregulation is a key driver for the initiation and progression of MASH MCJ is a key regulator of mitochondrial metabolism and knockdown improves steatosis, inflammation and fibrosis in MASH preclinical models MITO-1041 is a GalNAc MCJ siRNA which shows promise as a safe and effective therapy that can be used alone or in combination…Read more
day: Combination & Sequential Therapy Focus Day